Micropos Medical (MPOS) Q2 2024 earnings summary

Executive summary

• Net sales for Jan–Jun 2024 increased to 2,012 Tkr from 969 Tkr year-over-year, with Q2 sales at 1,200 Tkr versus 291 Tkr last year.

• Loss after financial items improved to -11,636 Tkr from -12,501 Tkr year-over-year; EPS was -0.08 kr compared to -0.09 kr.

• High market activity, including new installations in Switzerland and growing interest in the UK, Italy, and Iberia.

• Raypilot System gaining traction as SBRT adoption grows, supported by positive clinical studies and increased focus on patient quality of life.

Financial highlights

• Operating loss for Jan–Jun 2024 was -11,577 Tkr, an improvement from -12,449 Tkr year-over-year.

• Cash flow for the period was 12,483 Tkr, with cash and equivalents at 18,501 Tkr at period end.

• Equity increased to 20,363 Tkr from 19,568 Tkr year-over-year, supported by a new share issue and option exercise.

• Solid equity ratio maintained at 74%.

• Number of shares outstanding rose to 151,926,703 from 138,772,195.

Outlook and guidance

• Anticipates SBRT to become standard for prostate cancer radiotherapy in Europe within two years, driving demand for Raypilot System.

• Ongoing efforts to expand into routine care and increase adoption beyond research-focused clinics.

• MDR certification work continues, with current CE certificate secured; full MDR compliance expected by year-end.